PTPI (Petros Pharmaceuticals, Inc.) Multiplikator Forward P/S
The forward P/S valuation for Petros Pharmaceuticals (PTPI), with GURU.Markets data illustrated on this chart, confirms the impact of men's health patents and strict FDA oversight. Meanwhile, the 0.20 level serves as a critical benchmark. Business efficiency is based on outsourcing production via CMOs to reduce costs, while revenue scaling relies on the development of direct-to-consumer digital sales.
PTPI (petrospharma.com): rincian analitis lan laporan miturut indikator
- rega pasar lan target rega analis:
- indikator valuasi pasar bisnis:
- statistik nilai buku emiten:
- data utang lan likuiditas:
Utang marang Ekuitas Petros Pharmaceuticals|PTPI - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Petros Pharmaceuticals Inc|PTPI - Gunggung kewajiban utang perusahaan|Utang marang nilai buku Petros Pharmaceuticals Inc|PTPI - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Petros Pharmaceuticals|Rasio cepet petrospharma.com
- indikator pendapatan resik lan kelipatan nilai:
PTPI - Bathi pungkasan|Proyeksi bathi mangsa ngarep Petros Pharmaceuticals|PTPI - Pangali P/E|Rega marang bathi mangsa ngarep Petros Pharmaceuticals|PTPI - Koefisien bali modal nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Petros Pharmaceuticals Inc|PTPI - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) Petros Pharmaceuticals|PTPI - Bathi resik saben saham (EPS TTM)|Wutah bathi EPS kuartalan petrospharma.com|PTPI - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep Petros Pharmaceuticals
- rincian pendapatan lan dodolan emiten:
Analisis komprehensif perusahaan:Petros (PTPI)
For the biopharmaceutical company Petros Pharmaceuticals (PTPI), whose operations are strictly regulated by FDA standards, the key value driver is the expected commercialization of its products. The forward P/S ratio compares current market capitalization with projected annual revenue, allowing investors to filter out emotional noise and determine the fair value of assets, utilizing this chart to identify entry points when the business potential is undervalued.
Pesaing wigati
Multiplikator Forward P/S HLN (Haleon PLC)|Multiplikator Forward P/S Kenvue Corp KVUE|Verona Pharma PLC - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep jyongbio.com|LGND: Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan AMRX|Rasio rega marang prakiraan pendapatan Perrigo Company|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Alvotech ALVO|Multiplikator Forward P/S LQDA|GLPG: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S ANIP (ANI Pharmaceuticals, Inc.)|Rasio kapitalisasi marang dodolan sing dikarepake MannKind Corp (MNKD)|AMPH: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan PCRX (Pacira)|ARS Pharmaceuticals (SPRY) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan TBPH|AQST (Aquestive Corp) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan scPharmaceuticals Inc. (SCPH)|Multiplikator forward rega marang pendapatan TECX (Tectonic Therapeutic, Inc.)|TNXP (Tonix Pharmaceuticals Holding) - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan SXT Pharmaceuticals SXTC|Rega forward marang dodolan EPRX|BHST - Rasio rega marang prakiraan pendapatan|eXoZymes (EXOZ) - Multiplikator forward rega marang pendapatan|ORMP: Multiplikator Forward P/S|ENTX: Rasio rega marang pendapatan sing dikarepake|HYFT (ipatherapeutics.com) - Multiplikator Forward P/S|Multiplikator Forward P/S ABVC BioPharma|Rasio rega marang prakiraan pendapatan Cumberland Pharmaceuticals Inc. (CPIX)|QNTM (Quantum BioPharma Ltd.) - Rega forward marang dodolan|Multiplikator Forward P/S FGEN (fibrogen.com)|Telomir Pharmaceuticals (TELO) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|RANI - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Synergy CHC SNYR|RLYB: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Lexaria (LEXX)|Rasio rega marang prakiraan pendapatan Pulmatrix|Kapitalisasi marang prakiraan pendapatan PTHL (ftzy.com.cn)|Multiplikator Forward P/S APM|Lyra Therapeutics, Inc. - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S IBO (impactbiomedinc.com)|TNFA: Kapitalisasi marang prakiraan pendapatan|YCBD - Rasio rega marang prakiraan pendapatan|PRFX - Multiplikator Forward P/S|CYTO (altamiratherapeutics.com) - Multiplikator forward rega marang pendapatan|LIPO - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan OPTN|Pieris Pharmaceuticals Inc (PIRS) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S PROC|Multiplikator Forward P/S Qilian International Corp (QLI)|ACELYRIN, Inc. - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S tffpharma.com TFFP
